KIF20A peptide

KIF20A peptide refers to a cancer vaccine or immunotherapeutic agent based on peptides derived from the kinesin family member 20A (KIF20A), a motor protein involved in cell division and intracellular trafficking. KIF20A is overexpressed in various cancers, including pancreatic and breast cancer, and is associated with poor prognosis[4][5][6]. The mechanism of action involves stimulating an immune response against tumor cells expressing KIF20A by presenting its epitope(s) as a vaccine, thereby enhancing cytotoxic T lymphocyte activity against these cells[2][3]. Clinical studies have evaluated the safety and immunogenicity of KIF20A-derived peptides in combination with chemotherapy (e.g., gemcitabine) for advanced pancreatic cancer[3]. The approach aims to improve disease control by targeting tumor-specific antigens while sparing healthy tissue.

Other names

KIF20A-derived peptideKIF-20A-derived peptideKIF 20A-derived peptideRAB6KIFL-derived peptideRAB-6KIFL-derived peptideRAB 6KIFL-derived peptide